Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis.

Bioorg Med Chem

Department of Earth Sciences, University of Pisa, Via Santa Maria 53-55, 56100 Pisa, Italy; Research Center "E. Piaggio", Università di Pisa, Pisa 56122, Italy. Electronic address:

Published: September 2020

AI Article Synopsis

  • Transthyretin (TTR) is a protein that carries hormones like thyroxine and interacts with amyloid-β, potentially offering protection against Alzheimer's disease.
  • Dissociation of TTR into monomers is a key step that leads to the formation of harmful amyloid fibrils associated with diseases like systemic ATTR amyloidosis.
  • Researchers have developed new compounds, specifically monoaryl-derivatives, that can bind to TTR and stabilize its tetramer form, with one derivative (1d) showing effectiveness similar to the known inhibitor diflunisal in preventing TTR-related fibrillogenesis.

Article Abstract

Transthyretin (TTR) is a ß-sheet-rich homotetrameric protein that transports thyroxine (T4) and retinol both in plasma and in cerebrospinal fluid. TTR also interacts with amyloid-β, playing a protective role in Alzheimer's disease. Dissociation of the native transthyretin (TTR) tetramer is widely accepted as the critical step in TTR amyloids fibrillogenesis, and is responsible for extracellular deposition of amyloid fibrils. Small molecules, able to bind in T4 binding sites and stabilize the TTR tetramer, are interesting tools to treat and prevent systemic ATTR amyloidosis. We report here the synthesis, in vitro evaluation and three-dimensional crystallographic analyses of new monoaryl-derivatives in complex with TTR. Of the derivatives reported here, the best inhibitor of TTR fibrillogenesis, 1d, exhibits an activity similar to diflunisal.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2020.115673DOI Listing

Publication Analysis

Top Keywords

transthyretin ttr
8
ttr tetramer
8
ttr
7
monoaryl derivatives
4
derivatives transthyretin
4
transthyretin fibril
4
fibril formation
4
formation inhibitors
4
inhibitors design
4
design synthesis
4

Similar Publications

A Case of Transthyretin Cardiac Amyloidosis Coexisting With Rheumatoid Arthritis.

Cureus

December 2024

Graduate Medical Education (GME) Internal Medicine, Mary Washington Healthcare, Fredericksburg, USA.

Cardiac amyloidosis is a rare but increasingly recognized cause of heart failure, often underdiagnosed until later stages of the disease. This report describes a case of transthyretin amyloidosis (ATTR) in a 68-year-old male patient with a significant medical history of rheumatoid arthritis (RA), a combination seldom documented in the literature. The patient presented with progressive symptoms of heart failure, and diagnostic testing confirmed ATTR cardiac amyloidosis through pyrophosphate (PYP) scanning.

View Article and Find Full Text PDF

Transthyretin-Related Familial Amyloidosis Polyneuropathy with Spinal Cord Damage: A Case Report.

Int Med Case Rep J

January 2025

Department of Neurology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Cerebrovascular Disease (Stroke) Clinical Medical Research Center, Regional Medical Center for Neurological Diseases of Henan Province, Luoyang, People's Republic of China.

Introduction: Transthyretin protein-related familial amyloidosis polyneuropathy (TTR-FAP) is an autosomal dominant genetic disease caused by mutations in the TTR gene. The disease is characterized primarily by peripheral and autonomic nerve damage. Disease progression is associated with frequent involvement of the heart, lungs, kidneys, eyes, and other organs.

View Article and Find Full Text PDF

Variant transthyretin amyloidosis cardiomyopathy (ATTRv-CM) is a rare form of cardiac amyloidosis associated with many possible mutations in the transthyretin gene, presenting as various distinct clinical phenotypes. Among these, the His108Arg mutation is the most prevalent TTR variant in Austria. However, data describing its clinical phenotype are lacking.

View Article and Find Full Text PDF

Hereditary transthyretin amyloidosis (ATTRv) is an autosomal-dominant systemic disease, where amyloid fibrils accumulate especially in the peripheral and autonomic nervous systems and in the heart. The aim of the present work was to outline the follow-up and type of management received by asymptomatic carriers (ACs) and stage 1 ATTRv patients in Spain. A cross-sectional, non-interventional study was conducted throughout seven experienced hospitals in Spain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!